How much are patients willing to pay for an earlier alleviation of influenza?

International Congress Series

Volumn 1219, Issue C, 2001, Pages 67-71

  Carrat, Fabrice ^a   Sahler, Camille ^a   Le Galès, Catherine ^b   Schwarzinger, Michael ^b   Nicolas, Marlène ^c   Bungener, Martine ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c Laboratoire Glaxo Wellcome   (France)

Author keywords

Cost benefit studies; Influenza; Willingness to pay

Indexed keywords

EID: 0012943693     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00327-2     Document Type: Article

References (6)

1. Monto, A.S., Fleming, D.M., Henry, D., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Infect. Dis. 180 (1999), 254–261.
2. Birch, S., Gafni, A., O'Brien, B., Willingness to pay and the valuation of programmes for the prevention and control of influenza. Pharmacoeconomics 16:Suppl. 1 (1999), 55–61.
3. Carrat, F., Sahler, C., Leruez, M., et al. Quantifying the burden of influenza: a prospective household contact study in France. Osterhaus, A., et al. (eds.) Options for the Control of Influenza IV, Excerpta Medica International Congress Series, 2001, Elsevier, Amsterdam, 52–57.
4. Smith, R.D., The discrete-choice willingness-to-pay question format in health economics: should we adopt environmental guidelines?. Med. Decis. Making 20 (2000), 194–206.
5. Hannemann, M., Loomis, J., Kanninen, B., Statistical efficiency of double-bounded dichotomous choice contingent valuation. Am. J. Agric. Econ. 73 (1991), 1255–1263.
6. Monto, A.S., Webster, A., Keene, O., Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J. Antimicrob. Chemother. 44:Suppl. B (1999), 23–29.